|
|
|
|
J Pharm Biomed Anal 2010,Nov,02;53(3):350-8; (PMID: 20457503)
[...]The concentrations of chlorogenic acid, caffeic acid, luteoloside, baicalin, ursodesoxycholic acid (UDCA), and chenodeoxycholic acid (CDCA) were determined with the HPLC-DAD/ELSD as reference method.[...]
|
|
|
Antioxid Redox Signal 2010,Aug,01;13(3):259-68; (PMID: 20055754)
The cytoprotective mechanisms of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) have not been fully clarified.[...]
|
|
|
J Hepatol 2010,Aug,01;53(2):313-7; (PMID: 20472317)
[...]BACKGROUND & AIMS: In patients with primary sclerosing cholangitis (PSC) treated with ursodeoxycholic acid (UDCA), dominant stenoses are associated with reduced survival free of liver transplantation and the role of [...]
|
|
|
Pediatr Transplant 2010,Aug,01;14(5):618-21; (PMID: 20051023)
[...] who underwent HSCT and received a combined prophylactic regimen of intravenous heparin, oral glutamine, and ursodiol was undertaken. Analysis of the outcome of VOD revealed only one clinical case with acute myeloid leukemia[...]
|
|
|
Expert Rev Gastroenterol Hepatol 2010,Aug,01;4(4):473-88; (PMID: 20678020)
[...]Despite extensive research, there is currently no effective medical treatment. Multiple drugs are shown to be ineffective in halting disease progression, including ursodeoxycholic acid, the most widely evaluated drug. High-dose ursodeoxycholic acid (28-30 mg/kg/day) was recently shown to increase the adverse events rate.[...]
|
|
|
Gastroenterol Clin Biol 2010,Aug,01;34(6-7):380-7; (PMID: 20537830)
[...] dilations that could suggest a specific genetic background in this setting. This variant shows similar sensitivity to ursodeoxycholic acid and may be partly reversible under long-term therapy. In summary, we describe here a peculiar cholangiographic phenotype of the LPAC syndrome characterized by single-shaped large [...]
|
|
|
Neurogastroenterol Motil 2010,Aug,01;22(8):866-73, e232; (PMID: 20426797)
[...]) contractility and chronic inflammatory changes in the mucosa have been reported in patients with cholesterol gallstones (GS). Ursodeoxycholic acid (UDCA) restores GB contractility and antagonises liver macrophage activation. In the colon[...]
|
|
|
Hepatology 2010,Aug,01;52(2):667-77; (PMID: 20683964)
Ursodeoxycholic acid (UDCA) induces bicarbonate-rich hypercholeresis by incompletely defined mechanisms that involve the stimulation of [...]
|
|
|
Hepatology 2010,Aug,01;52(2):472-9; (PMID: 20683947)
In uncontrolled clinical studies, ursodeoxycholic acid (UDCA) had a beneficial effect on nonalcoholic steatohepatitis (NASH). However, a large controlled trial using [...]
|
|
|
J Neurol Sci 2010,Jul,15;294(1-2):43-50; (PMID: 20471037) [FULL TEXT AVAILABLE]
[...]. Various inhibitors of this pathway, such as pyrrolidine dithiocarbamate (PDTC) and ursodeoxycholic acid (UDCA), have been shown to have beneficial effects on dystrophic (mdx) muscle.[...]
|
 1 2 3 4 5 6 7 8 
|
|
